Dynavax Technologies reported $955.4M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adma Biologics ADMA:US USD 224.1M 1.32M
Agenus AGEN:US USD 251.43M 37.5M
Amgen AMGN:US USD 24.06B 4.74B
AstraZeneca AZN:LN USD 20.22B 693M
Astrazeneca AZN:US USD 20.22B 693M
Biogen BIIB:US USD 9.77B 24.9M
Biomarin Pharmaceutical BMRN:US USD 2.68B 165.1M
Bristol Myers Squibb BMY:US USD 26.8B 3.39B
Chimerix CMRX:US USD 291.12M 240.35M
Gilead Sciences GILD:US USD 13.9B 723M
Glaxosmithkline GSK:US GBP 20.25B 33.94B
Idera Pharmaceuticals IDRA:US USD 30.07M 4.48M
Minerva Neurosciences NERV:US USD 44.84M 5.2M
Nektar Therapeutics NKTR:US USD 599.48M 66.05M
Neurocrine Biosciences NBIX:US USD 1.21B 186.2M
Novartis NOVN:VX USD 36.95B 1.19B
Regeneron Pharmaceuticals REGN:US USD 15.43B 101.3M
Roche Holding ROG:VX 30.32B 5.31B
Sarepta Therapeutics SRPT:US USD 2.63B 156.63M
Tg Therapeutics TGTX:US USD 182.92M 19.64M
Vertex Pharmaceuticals VRTX:US USD 12.27B 767.5M